Article Listing - Zeneca Reports Accolate Plans
SP-PG FOR KAPOSI'S SARCOMA?
23 March 1992
A new experimental compound which could prove useful as a treatment for AIDS patients with Kaposi's sarcoma has been described...
US APPRO OF J&J's HEP C TEST
23 March 1992
The US Food and Drug Administr-ation has licensed Johnson and Johnson's new sensitive blood screening test for the hepatitis C...
UK MARKETING OF MAXEPA
23 March 1992
The only prescription formulation of the fish oil-derived omega-3 fatty acid product Maxepa is to be marketed in the UK...
HYPOLIPIDEMICS INFO
23 March 1992
The Belgian Ministry of Health has issued a transparency sheet on hypolipidemics - the third in its series of comparative...
HOW EC PATENT EXTENSION IS SHAPING UP
23 March 1992
Last week, the Council of the Commission of the European Communities passed to the Europ-ean Parliament its common position on...
FROM A RESEARCH-LED TO A MARKET-DRIVEN FIRM
23 March 1992
The task of pharmaceutical industry management is to achieve the best possible balance between the constant pull of the...
GENZYME CYSTIC FIBROSIS BUY-BACK
23 March 1992
Genzyme Corp and Neozyme say that, subject to completion of a proposed public financing of newly-formed Neozyme II Corp, Gen-zyme...
FRANCE PROBES GLAXO'S IMIGRAN PROMOTION
23 March 1992
The French government has commissioned a report on the pharmaceutical industry's promotional methods, following what it considers to be excessively...
CHILE COMPLETES ITS PATENT LAWS REFORMS
23 March 1992
One of the many features which differentiate the Chilean pharmaceutical sector from that of other Latin American countries is that...
US FDA "SHOULD BAN SPEAKER LISTS"
23 March 1992
Among the views presented to the US Food and Drug Administra-tion on its proposed draft guideline on Drug Company-Sponsored Activities...
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
